ArticleInternational journal of clinical oncology2026
Prophylactic intravenous dexamethasone is associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma: a multicenter prospective cohort study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous toxicity is common during enfortumab vedotin plus pembrolizumab, but evidence for prophylaxis is limited. We evaluated whether institutional prophylactic intravenous dexamethasone before enfortumab vedotin was associated with reduced cutaneous toxicity in locally advanced or metastatic urothelial carcinoma.
methodsThis multicenter prospective cohort enrolled 172 patients at 11 Japanese institutions. Before enrollment, three institutions adopted fixed dexamethasone (6.6 mg) premedication and eight did not; policies remained unchanged, and patients were not individually allocated. The primary endpoint was any-grade skin reaction. Best radiographic response was a prospectively specified exploratory analysis, and progression-free survival (PFS) was evaluated post hoc.
resultsForty-one patients were treated under the dexamethasone-premedication policy and 131 under the no-premedication policy. Any-grade skin reactions occurred in 36.6% and 64.9% of patients, respectively (P = 0.003), and grade ≥ 2 reactions occurred in 14.6% and 35.1% (P = 0.022). Dexamethasone was independently associated with lower risks of any-grade (adjusted odds ratio, 0.35; 95% confidence interval, 0.16-0.76) and grade ≥ 2 reactions (adjusted odds ratio, 0.27; 95% confidence interval, 0.10-0.73). Cumulative enfortumab vedotin exposure through two cycles was similar. In exploratory analyses, objective response rates were 61.1% and 63.1%; median PFS was not reached, and 6-month PFS rates were 67.3% and 73.9%, respectively (hazard ratio, 1.28; 95% confidence interval, 0.68-2.39; log-rank P = 0.440).
conclusionsAn institutional dexamethasone-premedication strategy was associated with reduced cutaneous toxicity during first-line enfortumab vedotin plus pembrolizumab. Exploratory analyses found no significant differences in response or PFS; adequately powered studies with longer follow-up should determine whether dexamethasone premedication affects antitumor efficacy.
Indexed as
Identifiers
42687064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.